עיניים

ICO: Long-Term Safety Data On XALATAN® Presented

PEAPACK, NJ — May 1, 2002 — Data presented for the first time at the XXIXth International Congress of Ophthalmology in Sydney, Australia, show that long-term (5-year) adjunctive treatment with XALATAN® (latanoprost ophthalmic solution) presented no new safety concerns and effectively lowered intra-ocular pressure (IOP) in patients with open-angle glaucoma (OAG). XALATAN® is the only prostaglandin analogue used in the treatment of OAG with 5-year efficacy and safety data to support its long-term use.

The data show that the IOP-lowering benefit of adjunctive therapy with XALATAN once daily was sustainable over 5 years. IOP was reduced by an average of 6.3 mmHg at 36 months, 5.9 mmHg at 48 months, and 6.0 mmHg at 60 months. During the 5-year study, IOP was well controlled without treatment modification or the need for surgery in 72 percent of patients.

"This study shows that XALATAN is effective and well tolerated both locally and systemically for long-term management of elevated IOP in open-angle glaucoma as adjunctive therapy," said Professor Albert Alm, Department of Ophthalmology, Uppsala University Hospital, Sweden.

The study was conducted as a two-year extension of a three-year open-label trial in 519 patients with OAG and uncontrolled IOP, despite previous treatment; there were 380 participants in the two-year extension. IOP was measured regularly every four months until month 48, and then every six months.

לכתבה המלאה

0 תגובות

השאירו תגובה

רוצה להצטרף לדיון?
תרגישו חופשי לתרום!

כתיבת תגובה

מידע נוסף לעיונך

כתבות בנושאים דומים

© ‫ e-Med
 כל הזכויות שמורות

 

התכנים המוצגים באתר זה מיועדים לאנשי צוות רפואי בלבד

אם כבר נרשמת, יש להקליד את פרטי הזיהוי שלך
עדיין לא נרשמת? באפשרותך לבצע רישום כאן
להרשמה לאתר